Zoetis delivered solid full-year 2025 results, with revenue reaching $9.5 billion, growing 6% on an organic operational basis, and adjusted net income growing 7% organically to $2.8 billion. Performance was driven by a diversified portfolio, with International markets growing 8% operationally and Livestock growing 8%, while U.S. growth moderated to 4% due to macroeconomic pressures on pet owners. Key growth drivers included the Simparica franchise (up 12% operationally to $1.5 billion) and Diagnostics (up 13%), partially offset by a 3% operational decline in the OA pain franchise. Looking ahead to 2026, management guides for 3% to 5% organic operational revenue growth and adjusted EPS of $7.00 to $7.10, reflecting confidence in the company's resilience and pipeline despite near-term competitive and macro headwinds.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $9.50 Billion | +2% Reported / +6% Organic Operational |
| Adjusted Net Income | $2.80 Billion | +6% Reported / +7% Organic Operational |
| Adjusted EPS | N/A | +6% Operational / +10% Organic Operational |
| U.S. Revenue | $5.10 Billion | +4% Organic Operational |
| International Revenue | N/A | +8% Organic Operational |
| Simparica Franchise Revenue | $1.50 Billion | +12% Operational |
| Livestock Revenue | $2.80 Billion | +8% Organic Operational |
| Diagnostics Revenue | N/A | +13% Operational |
| OA Pain Revenue | $568 Million | -3% Operational |
Zoetis is leveraging its 'Science-to-Scale' model to drive growth through innovation, highlighted by 185 geographic expansions and lifecycle innovations in 2025. The company is preparing for significant pipeline contributions, specifically the launch of long-acting oral OA products Lanivia and Portela in international markets in 2026, with U.S. approval expected in 2027. This focus on innovation is critical for extending the growth runway and maintaining leadership in parasiticides and dermatology.
The Diagnostics segment is emerging as a strategic growth engine, delivering 13% operational revenue growth in 2025. This growth is driven by AI-enabled capabilities like VetScan Imagyst and new launches such as Vetscan Optocell. Management views diagnostics not just as a revenue stream but as a tool to strengthen the overall portfolio and pioneer diagnosis-driven therapeutic areas, reinforcing the company's integrated healthcare approach.
International markets are becoming an increasingly important growth driver, delivering 8% organic operational revenue growth compared to 4% in the U.S. This strength was broad-based across Companion Animal and Livestock, with specific highlights including double-digit growth for Simparica Trio internationally. This geographic diversification mitigates U.S. macro headwinds and leverages rising protein demand and pet humanization trends globally.
Management is executing a strategic pivot in Livestock following the MFA divestiture, focusing on prevention and higher-value products. The segment delivered 8% organic operational growth, driven by vaccines, aquaculture, and cattle health. This demonstrates the success of their focused portfolio strategy and the strength of their commercial execution in a sector benefiting from long-term protein consumption trends.
Zoetis is actively deploying capital to enhance shareholder value, returning over $3.2 billion through buybacks and $800 million through dividends in 2025. The recent convertible bond offering supports a $1.75 billion buyback while maintaining a strong balance sheet. This aggressive capital deployment signals management's confidence in cash flow generation and commitment to returning capital.
The company is undertaking a major ERP system transition and fiscal year alignment to calendar year 2026. While creating short-term noise in revenue recognition (accelerating sales into Q4 2025), this strategic move is designed to modernize operations, eliminate reporting lags, and provide greater speed and productivity in the long term.
The U.S. market is experiencing significant macroeconomic pressure, specifically from Gen Z and millennial pet owners, leading to a decline in therapeutic visits and doses. Management noted 'greater price sensitivity and tighter household budgets,' which contributed to U.S. Companion Animal growth slowing to 4% and Key Dermatology growth decelerating to 1% in Q4. This consumer weakness could persist longer than anticipated if economic conditions do not improve.
The OA Pain franchise, specifically Librela, is facing headwinds, declining 3% operationally for the year and 16% in the U.S. Management acknowledged ongoing dialogue with regulators regarding adverse events and the need for education on the benefit-risk profile. While they claim sales are stabilizing, the decline in a key growth driver and the scrutiny around safety present a risk to the company's growth narrative.
Competitive intensity is rising, with management noting 'elevated promotional launch activity' in parasiticides and dermatology. The entrance of new JAK competitors internationally and aggressive promotional activity from competitors in the U.S. are pressuring market share and forcing Zoetis to increase its own promotional spending or risk losing share in key franchises like Simparica and Apoquel.
The 2026 guidance of 3% to 5% organic revenue growth represents a significant deceleration from the 6% achieved in 2025 and the historical 8-9% average. Management attributes this to macro pressures and competition, but it suggests that the company's core growth engines are maturing or facing stronger headwinds than previously expected.
The accounting change regarding fiscal year alignment and the elimination of the one-month reporting lag is creating complexity in financial comparisons. The acceleration of sales into Q4 2025 (adding 30-40 bps) and the deferral of revenue into 2026 make year-over-year comparisons difficult and could obscure underlying operational performance, potentially confusing investors in the near term.
Overall: Management maintained a confident and composed demeanor throughout the call, emphasizing the 'resilience' and 'durability' of their business model. While acknowledging 'dynamic' and 'challenging' macroeconomic conditions in the U.S., particularly regarding consumer price sensitivity, both Kristin Peck and Wetteny Joseph projected a tone of assured control regarding the company's strategic direction and execution capabilities.
Confidence: HIGH - Management displayed high confidence in their long-term strategy, citing a robust pipeline with 12 potential blockbusters and strong market positions. They provided specific guidance ranges and detailed operational drivers, suggesting a strong grasp of the business despite external uncertainties.
3% to 5% Organic Operational
$9.825 Billion to $10.025 Billion
3% to 6% Organic Operational
$2.975 Billion to $3.025 Billion
$7.00 to $7.10
$6.65 to $6.75
Hedging & Uncertainty: Management frequently used qualifiers to temper expectations regarding the near-term macro environment and competitive landscape. Phrases like 'we expect to moderate as the year progresses,' 'believe the long-term fundamentals... are strong,' and 'we anticipate' were used to frame guidance. Wetteny Joseph notably hedged on the impact of the accounting changes, stating, 'We do not expect to recur at the end of fiscal 2026' regarding the sales acceleration, and 'we have not completed the process yet' regarding the ERP transition, leaving room for execution risk.
The essential and resilient nature of animal health... provide a durable foundation for growth. - Kristin Peck, Chief Executive Officer
We are navigating a dynamic operating environment shaped by macroeconomic and competitive pressures. - Kristin Peck, Chief Executive Officer
We are guiding to a range of 3% to 5% organic operational revenue growth... This outlook reflects our confidence in our ability to execute. - Kristin Peck, Chief Executive Officer
We do not see any meaningful contributions here [from Merck's product]. - Wetteny Joseph, Chief Financial Officer
We are seeing signs that our strategy is working, supported by stabilizing monthly overall sales trends. - Kristin Peck, Chief Executive Officer
We are taking targeted actions to offset these pressures by optimizing our channel mix. - Kristin Peck, Chief Executive Officer
Analyst Sentiment: Analysts were highly focused on the mechanics of the fiscal year alignment and the specific accounting shifts impacting Q4 2025 and 2026 comparables. There was also significant skepticism regarding the sustainability of growth in the face of rising competition and U.S. macro headwinds.
Management Responses: Management, particularly CFO Wetteny Joseph, was patient and detailed in explaining the accounting changes, repeatedly clarifying that there is no 'extra month' of sales but rather a timing shift. They defended the 2026 guidance as prudent given the competitive landscape and macro factors, while emphasizing the strength of the underlying portfolio.
Analysts pressed heavily on the impact of the fiscal year alignment and ERP transition, seeking clarity on how much revenue was pulled forward into Q4 2025 versus pushed out to 2026. Wetteny Joseph clarified that the benefit in Q4 was 30-40 basis points and that 2026 guidance is on a comparable basis.
There was detailed questioning about the competitive landscape, specifically regarding new JAK inhibitors in dermatology and parasiticides. Management acknowledged the competitive pressure but emphasized their 'first-mover advantage' and the strength of their omnichannel strategy.
The U.S. macro environment was a key topic, with analysts asking about the 'elasticity of demand' and pricing power. Management admitted to price sensitivity but maintained that demand for essential care remains resilient.
Questions regarding the performance of Librela and the OA pain franchise were prominent, with analysts looking for signs of stabilization. Management cited 'stabilizing monthly trends' and high satisfaction scores to support their confidence in a return to growth.
Zoetis remains a premier animal health franchise with a durable business model supported by a diversified portfolio and strong competitive moats. While the 3-5% growth guidance for 2026 is conservative relative to historical performance, it reflects prudent management of near-term headwinds, including U.S. macro pressure and competitive launches. The company's strategic focus on high-growth areas like Diagnostics (13% growth) and Livestock (8% growth), combined with a robust pipeline featuring 12 potential blockbusters, positions it well for a re-acceleration in 2027 and beyond. The aggressive share buyback program ($3.2B in 2025) underscores management's confidence in the company's cash generation and intrinsic value. Despite the noise from accounting changes and temporary softness in the U.S. market, the long-term fundamentals of protein consumption and pet humanization remain intact, making ZTS a solid core holding for investors seeking stability and innovation.
Management noted economic pressure on Gen Z and millennial pet owners, leading to tighter household budgets and a decline in therapeutic visits. This suggests a trade-down behavior in non-emergency veterinary care.
Livestock growth is being driven by rising global protein consumption linked to GDP growth and income increases. Additionally, the use of GLP-1 drugs in the U.S. is expected to drive higher demand for meat and dairy, benefiting the livestock sector.
While Zoetis secured price increases (2-3%), management acknowledged that veterinary clinics raised prices significantly over the last three years, leading to 'price fatigue' among pet owners and contributing to lower visit volumes.
Guidance assumes FX rates as of late January 2026. The transcript notes FX had a favorable impact on margins in 2025, but the guidance implies a more neutral or slightly headwind impact going forward based on current rates.